Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 4/20 | 0.61 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL244641 | 0.86 | SCD (0.58) | SCDCHRM4PPARA | |
| SCHEMBL5608014 | 0.84 | SCD (0.58) | SCDCHRM4MAOBCXCR4GAA | |
| SCHEMBL243885 | 0.80 | SCD (0.65) | SCD | |
| SCHEMBL4030640 | 0.79 | SMN1; SMN2 (0.54) | SCDCHRM4MAOBCXCR4MMP13 | |
| SCHEMBL775097 | 0.78 | LCK (0.56) | SCDCHRM4CXCR4GAAPPARA | |
| SCHEMBL13082592 | 0.78 | MMP13 (0.56) | SCDCHRM4MMP13 | |
| SCHEMBL3369993 | 0.77 | SCD (1.00) | SCD | |
| SCHEMBL3454999 | 0.76 | SCD (0.59) | SCDCHRM4MAOBPPARACACNA1G | |
| SCHEMBL25124267 | 0.76 | ADORA2A (0.44) | SCDCHRM4 | |
| SCHEMBL3370632 | 0.75 | SCD (0.80) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024583-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-01-23 | — | — | US | disclosed |
| US-8501746-B2 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2013-08-06 | — | — | US | disclosed |
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| WO-2007143597-A9 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| EP-2029572-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
| US-20090156615-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885CHRM4 3687/4885MAOB 456/4885 |
| US-20090156615-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885CHRM4 3011/4885MAOB 510/4885 |
| US-20120004164-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885CHRM4 3011/4885MAOB 510/4885 |
| US-20140024583-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885CHRM4 3011/4885MAOB 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.